Streetbeat News

Analyst Ratings

C

GLNG

Citigroup analyst Christian Wetherbee has reinstated Golar LNG (NASDAQ:GLNG) with a Neutral rating and announced a $27 price target.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2023 | 10:35 am

HDSN

Canaccord Genuity analyst Austin Moeller has initiated coverage on Hudson Technologies (NASDAQ:HDSN) with a Buy rating and a price target of $15.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2023 | 10:34 am

PLUG

HSBC analyst Samantha Hoh has initiated coverage on Plug Power (NASDAQ:PLUG) with a Buy rating and a price target of $11.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2023 | 10:31 am

MORF

BTIG analyst Julian Harrison has downgraded Morphic Holding (NASDAQ:MORF) from Buy to Neutral.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2023 | 10:29 am

ACRX

HC Wainwright & Co. analyst Ed Arce maintains a 'Buy' rating on AcelRx Pharmaceuticals (NASDAQ:ACRX) but has lowered the price target from $8 to $5.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2023 | 10:19 am

KZR

HC Wainwright & Co. analyst Raghuram Selvaraju maintains a 'Buy' rating on Kezar Life Sciences (NASDAQ:KZR) and raises the price target from $18 to $20.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2023 | 10:17 am

ENLV

HC Wainwright & Co. analyst Raghuram Selvaraju maintains a 'Buy' rating on Enlivex Therapeutics (NASDAQ:ENLV) but lowers the price target from $15 to $12.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2023 | 10:15 am

ANGO

HC Wainwright & Co. analyst Yi Chen has initiated coverage on AngioDynamics with a Buy rating and a price target of $19.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2023 | 10:14 am

ENSC

HC Wainwright & Co. analyst Raghuram Selvaraju maintains a 'Buy' rating on Ensysce Biosciences (NASDAQ:ENSC) but has lowered the price target from $9 to $7.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2023 | 10:12 am

ANEB

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Anebulo Pharmaceuticals (NASDAQ:ANEB) and maintained a $6 price target.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2023 | 10:10 am